Sorry, you need to enable JavaScript to visit this website.



Strategic Plan

Read the DC Strategic Plan to Reduce Opioid Use, Misuse and Related Deaths [PDF]

Since LLDC was published in December 2018, much work has been done to meet the Plan goals. The following successes have helped move us closer to reaching our goal of reducing opioid use, misuse, and related deaths: 

  • Instituted an Opioid Fatality Review Board composed of 15 people from 10+ agencies/organizations across DC. The purpose of the Board is to examine the cases of opioid decedents, review existing data, and make recommendations.
  • Received approval on the innovative 1115 waiver that grew Medicaid coverage for behavioral health services including Psychosocial Rehabilitation Services, residential and inpatient Institutions for Mental Disease (IMD) stays, and recovery support services. Additionally, it removed co-pays for MOUD services and allows psychologists and other behavioral health professionals to bill Medicaid for certain services.
  • Increased Prescription Drug Monitoring Program (PDMP) registrations due to 2018 legislation requiring mandatory registration for providers: 2,586 users in 2018 → 16,277 users in 2019.
  • Launched public education campaigns, including an anti-stigma campaign, to increase awareness about opioid use, treatment, and recovery.
  • Awarded $1,150,000 in grants to 23 faith-based institutions to plan for opioid awareness activities and provide information about treatment and recovery services and supports; $960,000 will be available in FY 21 for 16 additional grants.
  • Expanded education and distribution of naloxone, including enabling 28 pharmacies across all 8 wards to distribute naloxone for free. Launched Text to Live (“LiveLongDC” to 888-811) to receive information about where to access treatment and free naloxone from 35 pharmacies and community sites.
  • Implemented Screening, Brief Intervention, Referral, and Treatment (SBIRT) in five emergency departments (with a sixth one launching soon) and the induction of medication for opioid use disorder (MOUD), in conjunction with peer engagement and referrals to community services and supports. Since program inception (May 2019), 258,052 screenings have been completed and 9,923 patients with risky alcohol or substance use behaviors were given a brief intervention to assess their willingness to change their behavior since program inception.
  • Expanded peer support across the District to include harm reduction services, treatment, and recovery support by growing the network of peer workers through programs such as Rapid Peer Responders and hospital peers who support patients after an overdose.
  • Expanded outreach capacity to include 6+ outreach teams who are working across the District to connect individuals to needed resources including MOUD, syringe exchange, naloxone, opioid use disorder (OUD) treatment, clothing, housing, and food.
  • Implemented Overdose Detection Mapping Application Program (ODMAP) to create an overdose tracking and response system that uses data to inform decision making and enables the deployment of outreach workers to the scene of an overdose.
  • In FY 20, distributed nearly 32,500 naloxone kits including 1,115 by FEMS at the scene of an overdose, and reversed more than 970 opioid overdoses with naloxone, which included more than 500 reversals by MPD.
  • Funded the expansion of buprenorphine in eight community clinics and established the Buprenorphine Drug Assistance Plan (BupDAP), a benefit for the uninsured or underinsured.
  • Created Supported Employment services for individuals with OUD, which has now become available in March 2020 for individuals with substance use disorders (SUD) under the 1115 Waiver.
  • Established four peer-operated centers that are focused on serving the needs of individuals with OUD. Since March 2020, they served 11,339 individuals and conducted 729 group sessions (mainly virtual).
  • Better characterized the supply of illegal opioids, including the discovery of new opioids, through advanced testing at the DFS opioid surveillance lab.
  • Enacted the provisions in the SAFE DC Act, which criminalizes synthetic drugs, including variants of fentanyl, based on the class of the chemical compounds, rather than the individual compound, strengthening law enforcement officials’ ability to test for and prosecute cases against sellers and distributors of these drugs. 


Read our strategic plan here.[PDF]

LIVE.LONG.DC. is Washington, DC’s Strategic Plan to reduce opioid use, misuse and related deaths.

Track our progress through our monthly reports:
April 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
May 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
June 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
July 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
August 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
September 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
October 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
November 2019-Monthly Progress Report-LIVE. LONG. DC. [PDF]
December 2019-Monthly Progress Report-LIVE LONG DC [PDF]
January 2020-Monthly Progress Report-LIVE. LONG. DC. [PDF]
February 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
March 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
April 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
May 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
June 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
July 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
August 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
September 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
October 2020 – Monthly Progress Report-LIVE.LONG.DC. [PDF]
November 2020 – Monthly Progress Report – LIVE.LONG.DC [PDF]
December 2020 – Monthly Progress Report-LIVE.LONG.DC [PDF]
January 2021 – Monthly Progress Report – LIVE.LONG.DC [PDF]
February 2021 – Monthly Progress Report – LIVE.LONG.DC [PDF]
March 2021 – Monthly Progress Report – LIVE.LONG.DC [PDF]



April 2021
PresentationsSummit Report

January 2021
Summit Report and Presentations

September 2020
PresentationsSummit Report

February 2020 
Summit Report, DFS ReportOCME ReportsDBH/DHCF Report

October 2019
PresentationsSummit Report

April 2019
PresentationsSummit Report

January 2019
PresentationsSummit Report

July 2019
PresentationsSummit Report

November 2018
Summit Report

August 2018
Summit Report

May 2018
Summit Report

March 2018
Summit Report

October 2017
Summit Report

To access treatment, call DBH’s Access Helpline at 1(888)7WE-HELP or 1-888-793-4357